Archiv
Archiv anzeigen:
bis


De-escalating Therapy in Localized Diffuse Large B-Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Lamy T et al. Blood 2017 Oct 23

Eliminating radiotherapy after immunochemotherapy did not affect outcomes in nonbulky, stage I–II disease.


Gene Therapy for Factor IX Deficiency Hemophilia

David Green, MD, PhD reviewing George LA et al. N Engl J Med 2017 Dec 7, Porteus M. N Engl J Med 2017 Dec 7

Infusion of a highly expressed mutant factor IX gene produced sustained therapeutic expression of factor IX anticoagulant activity.


How Active Should Active Surveillance Be for Prostate Cancer?

Robert Dreicer, MD, MS, FACP, FASCO reviewing Inoue LYT et al. Ann Intern Med 2017 Nov 28

Surveillance biopsies every other year rather than every year may be acceptable.


Diagnosis and Treatment of von Willebrand Disease

David Green, MD, PhD reviewing Sharma R and Flood VH. Blood 2017 Nov 30

A review article describes recent advances.


Cetuximab Ineffective for Esophageal Cancer

David H. Ilson, MD, PhD reviewing Sunthralingam M et al. JAMA Oncol 2017 Nov 1

Adding cetuximab to cisplatin, paclitaxel, and radiation therapy failed to improve overall survival in the nonoperative setting.


Ixazomib for Relapsed Myeloma

Michael E. Williams, MD, ScM reviewing Avet-Loiseau H et al. Blood 2017 Oct 20

Adding the proteasome inhibitor ixazomib to lenalidomide and dexamethasone improves outcomes for patients, regardless of their cytogenetic-risk status.


B-Cell Receptor Targeting in Indolent Lymphoma

Michael E. Williams, MD, ScM reviewing Dreyling M et al. J Clin Oncol 2017 Oct 4

The PI3K inhibitor copanlisib provided a 59% response rate in relapsed or refractory patients.


TP53 Mutations Are Prognostic in Mantle Cell Lymphoma

Michael E. Williams, MD, ScM reviewing Eskelund CW et al. Blood 2017 Oct 26, Cohen JB. Blood 2017 Oct 26

Mutations identified younger patients who had poor survival despite receiving intensive induction therapy.


High Rates of Marijuana Use in Cancer Patients

Peter Roy-Byrne, MD reviewing Pergam SA et al. Cancer 2017 Nov 15

In a state with legalized marijuana, 24% of patients had used marijuana in the last year, primarily for pain, nausea, stress, anxiety, and depression.


Osimertinib for Untreated EGFR-Mutated Advanced NSCLC

Anne S. Tsao, MD reviewing Soria J-C et al. N Engl J Med 2017 Nov 18

Progression-free survival was significantly prolonged with osimertinib versus standard treatment with erlotinib or gefitinib.


Archiv
Seite von 62
Editorial Member Board Empfehlungen

Prof. Dr. med. Christoph Rochlitz

Chefarzt Onkologie Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Daten nach 8 Jahren Follow-up in der WHI(Women’s Health Initiative)-Studie hatten eine gewisse Reduktion der Brustkrebstodesfälle durch eine Diät gezeigt, bei der weniger Fett, aber mehr Früchte, Gemüse und Ballaststoffe verzehrt wurden. Im jetzigen Bericht nach 16 Jahren Follow-up war diese Reduktion statistisch nicht mehr signifikant, es wurden aber eine leichte Verminderung der Zahl der prognostisch ungünstigeren Tumoren und weniger kardiovaskuläre Todesfälle berichtet.

Kommentar weiterlesen

Lung Cancer Rates Are Increasing Among Never-Smokers

Anne S. Tsao, MD reviewing Pelosof L et al. J Natl Cancer Inst 2017 Jul

From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.


Neoadjuvant CDK4/6 Inhibition for ER-Positive Breast Cancer

William J. Gradishar, MD reviewing Ma CX et al. Clin Cancer Res 2017 Aug 1

Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.


Nivolumab vs. Chemotherapy for Advanced Chemo-Naive NSCLC

Anne S. Tsao, MD reviewing Carbone DP et al. N Engl J Med 2017 Jun 22

First-line nivolumab did not prolong progression-free survival in chemo-naive patients with stage IV or recurrent PD-L1–positive non–small-cell lung cancer.


Prostatectomy vs. Observation for Localized Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing Wilt TJ et al. N Engl J Med 2017 Jul 13

Surgery did not significantly lower all-cause or prostate cancer mortality.


An Antidote for Dabigatran

David Green, MD, PhD reviewing Pollack CV Jr et al. N Engl J Med 2017 Jul 11

Idarucizumab rapidly reverses the effects of dabigatran in bleeding patients and in those undergoing urgent procedures.


Prophylaxis for Hemophilia A with Inhibitors

David Green, MD, PhD reviewing Oldenburg J et al. N Engl J Med 2017 Jul 10, Lillicrap D. N Engl J Med 2017 Jul 10

Emicizumab prevented bleeding and improved health-related quality of life.


Cetuximab vs. Bevacizumab for KRAS Wild-Type Advanced Colorectal Cancer

David H. Ilson, MD, PhD reviewing Venook AP et al. JAMA 2017 Jun 20, Lieu CH and Messersmith WA. JAMA 2017 Jun 20

Survival was similar with either agent when combined with first-line chemotherapy.


Bleeding Risk Is High in Elders Who Take Antiplatelet Drugs

Bruce Soloway, MD reviewing Li L et al. Lancet 2017 Jun 13

In a patient older than 75 who takes antiplatelet drugs for secondary prevention, a proton-pump inhibitor should be strongly considered.


Direct Oral Anticoagulants for Heparin-Induced Thrombocytopenia

David Green, MD, PhD reviewing Warkentin TE et al. Blood 2017 Jun 23

A systematic literature review finds DOACs safe and effective for HIT.


Combination Therapy for Metastatic Prostate Cancer

Robert Dreicer, MD, MS, FACP, FASCO reviewing James ND et al. N Engl J Med 2017 Jun 3, Fizazi K et al. N Engl J Med 2017 Jun 4

Adding abiraterone and prednisone to androgen-deprivation therapy significantly improved survival.